rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nutriband Inc.

NTRB · Nasdaq

Health CareMedical DevicesIn trend

NTRB stood above a rising 150-day average in 7 of the last 52 weekly readings, including each of the last 6 weeks. It is 36.5% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
In trend
Weeks in an uptrend
6 in a row
Industry in uptrend
29% -5 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
16 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 7 of 52 weeks.

21 Apr – 20 Oct
19%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+2 on the quarter
New · exited2 · 0
Reported value$1.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026174,927$558K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202662,494$199K-7,559−10.8%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202625,111$80K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202624,966$80K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202618,996$61K+18,996
NORTHERN TRUST CORPreduced · filed 13 Aug 202611,570$37K-2,375−17.0%
Haven Private, LLCunchanged · filed 29 Jul 202611,366$36K00.0%
BlackRock, Inc.added · filed 7 Aug 202610,662$34K+1,121+11.7%
OSAIC HOLDINGS, INC.reduced · filed 14 Aug 20263,684$12K-1,167−24.1%
Vanguard Global Advisers, LLCunchanged · filed 13 Aug 20262,700$8,61300.0%
31 Mar 2023 – 30 Jun 2026
91520Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Gareth Sheridan Company insiderChief Executive Officer · last 29 Jan 20250 · 0
Gerald Goodman Company insiderChief Financial Officer · last 23 Jan 20250 · 0
Serguei Melnik Company insiderPresident and Secretary · last 20 Mar 20243 · 0
Michael Davidov Company insiderDirector · last 31 Jul 20180 · 0
Vitalie Botgros Company insiderChairman of the BOD · last 15 Jan 20160 · 0

Same industry

RCEL Avita MedicalLeading+108%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+52%
PLSE Pulse BiosciencesLeading+51%
HAE HaemoneticsLeading+47%
INFU InfuSystems HoldingsLeading+34%
OBIO Orchestra BioMed HoldingsLeading+27%
SMTI Sanara MedTechLeading+25%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 31 Jan 202627.8%
Operating profit marginFY 2026 · to 31 Jan 2026-408%
Free cash flow marginFY 2026 · to 31 Jan 2026-252%
Return on capital employedFY 2026 · to 31 Jan 2026-123%
Research spendFY 2026 · to 31 Jan 202692.9%
Share count trendFY 2026 · to 29 Apr 20260.0%
Cash and equivalentsFY 2026 · to 31 Jan 2026$4.6M
Free cash flowFY 2026 · to 31 Jan 2026−$5.1M

Analyst forecasts

No analyst forecasts yet.